Project Oncology® podcast

Player FM - Internet Radio Done Right

اضافه شده در three سال پیش
Looks like the publisher may have taken this series offline or changed its URL. Please contact support if you believe it should be working, the feed URL is invalid, or you have any other concerns about it.

محتوای ارائه شده توسط ReachMD. تمام محتوای پادکست شامل قسمت‌ها، گرافیک‌ها و توضیحات پادکست مستقیماً توسط ReachMD یا شریک پلتفرم پادکست آن‌ها آپلود و ارائه می‌شوند. اگر فکر می‌کنید شخصی بدون اجازه شما از اثر دارای حق نسخه‌برداری شما استفاده می‌کند، می‌توانید روندی که در اینجا شرح داده شده است را دنبال کنید.https://fa.player.fm/legal

Mind The Business: Small Business Success Stories

1
Understanding Taxes as a Newly Formed Small Business - Part 2 of the Small Business Starter Kit 28:24

10 روز پیش28:24

پخش در آینده

لیست ها

پسندیدن

دوست داشته شد

28:24

In our second installment of the Small Business Starter Kit series - we’re tackling a topic that’s sometimes tricky, sometimes confusing, but ever-present: taxes. Hosts Austin and Jannese have an insightful conversation with entrepreneur Isabella Rosal who started 7th Sky Ventures , an exporter and distributor of craft spirits, beer, and wine. Having lived and worked in two different countries and started a company in a heavily-regulated field, Isabella is no stranger to navigating the paperwork-laden and jargon-infused maze of properly understanding taxes for a newly formed small business. Join us as she shares her story and provides valuable insight into how to tackle your business’ taxes - so they don’t tackle you. Learn more about how QuickBooks can help you grow your business: QuickBooks.com See omnystudio.com/listener for privacy information.…

Project Oncology®

اشتراک گذاری

خانه سری•Feed

بایگانی مجموعه ها ("فیدهای غیر فعال" status)

When? This feed was archived on March 01, 2025 21:08 (15d ago). Last successful fetch was on January 29, 2025 13:39 (2M ago)

Why? فیدهای غیر فعال status. سرورهای ما، برای یک دوره پایدار، قادر به بازیابی یک فید پادکست معتبر نبوده اند.

What now? You might be able to find a more up-to-date version using the search function. This series will no longer be checked for updates. If you believe this to be in error, please check if the publisher's feed link below is valid and contact support to request the feed be restored or if you have any other concerns about this.

Showcasing major breakthroughs in cancer care from worldwide clinical trials, Project Oncology® educates and assists the healthcare professionals who dedicate their lives to helping patients fight cancer. Here you’ll find leading oncologists discuss and share essential cancer care strategies for all different types of cancer. And as worldwide clinical trials continue to explore new screening tests and discover novel treatment options, you can rest assured that you’ll always catch the latest in cancer research with Project Oncology®.

149 قسمت

#Science #Health and Well-Being #Medicine #ReachMD

Project Oncology®

updated حدود یک سال پیش

اشتراک گذاری

خانه سری•Feed

بایگانی مجموعه ها ("فیدهای غیر فعال" status)

When? This feed was archived on March 01, 2025 21:08 (15d ago). Last successful fetch was on January 29, 2025 13:39 (2M ago)

Why? فیدهای غیر فعال status. سرورهای ما، برای یک دوره پایدار، قادر به بازیابی یک فید پادکست معتبر نبوده اند.

149 قسمت

#Science #Health and Well-Being #Medicine #ReachMD

All episodes

Project Oncology®

1
Predictive Models for CAR T-Cell Therapy: Personalizing R/R LBCL Care

10 weeks پیش

—

Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Matthew Matasar, MD When treating relapsed or refractory large B-cell lymphoma (R/R LBCL) with CAR T-cell therapy, the risk of adverse events is a key consideration. Models such as PhasED-Seq and CAR-HEMATOTOX can help clinicians assess the patient’s risk and personalize care plans regarding treatment selection and location, prophylactic regimen, and early intervention strategies. Tune in to hear Dr. Charles Turck and Dr. Matthew Matasar discuss the importance of these models in identifying individual factors, which can maximize the benefits of CAR T-cell therapy and reduce toxicities. Dr. Matasar is the Chief of the Division of Blood Disorders at Rutgers Cancer Institute and a Professor of Medicine at Rutgers Robert Wood Johnson Medical School.…

Project Oncology®

1
Mastering CAR-T Cell Therapy in R/R Large B-Cell Lymphoma: Adverse Event Management

10 weeks پیش

—

Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Sairah Ahmed, MD Guest: Caron A. Jacobson, MD The side effects associated with CAR T-cell therapy are very different than those seen with other cancer therapies and include cytokine-release syndrome (CRS) and neurotoxicity. It’s important to know how to recognize the signs of these adverse events and treat patients with relapsed or refractory large B-cell lymphoma early to avoid drastic quality-of-life impacts. To help improve patient safety and decrease hospital utilization, Dr. Charles Turck speaks with Drs. Caron Jacobson and Sairah Ahmed about the proper identification and management of these side effects in patients receiving CAR T-cell therapy. Dr. Jacobson is the Medical Director of the Immune Effector Cell Therapy Program at Dana-Farber Cancer Institute in Boston, and Dr. Ahmed is an Associate Professor in the Department of Lymphoma and Myeloma Division of Cancer Medicine at the University of Texas MD Anderson Cancer Center in Houston.…

Project Oncology®

1
Targeting HER2-Mutant NSCLC with Trastuzumab Deruxtecan: Initial Study Findings

10 weeks پیش

—

Host: Jacob Sands, MD Guest: Julia Rotow, MD In non-squamous non-small cell lung cancer (NSCLC), a small percentage of patients will have activating HER2 mutations. For these patients, the standard second-line therapy is docetaxel, but this can have poor response rates. That’s why the DESTINY-Lung03 trial examined the safety and efficacy of trastuzumab deruxtecan in patients with pretreated HER2-overexpressing non-squamous NSCLC. Here with Dr. Jacob Sands to share the findings from part 1 of this trial is thoracic medical oncologist Dr. Julia Rotow.…

Project Oncology®

1
Preventing Adverse Events in CAR T-Cell Therapy: The Evolution of Safety Protocols

10 weeks پیش

—

Guest: Tara Graff, DO, MS Host: Charles Turck, PharmD, BCPS, BCCCP While CAR T-cell therapy is an effective option for patients with certain blood cancers like lymphoma and myeloma, it’s associated with two common adverse events: cytokine release syndrome and neurotoxicity. Given those risks, safety protocols have evolved over time to include strategies like aggressive hydration, prophylactic use of corticosteroids, early intervention with tocilizumab, and multidisciplinary care. Joining Dr. Charles Turck to share her insights into how we can lower the risks of CAR T-cell therapy is Dr. Tara Graff, a medical oncologist who leads a community-based clinical trial program at Mission Cancer and Blood in Des Moines, Iowa.…

Project Oncology®

1
Treating Second-Line NSCLC: The Efficacy of ADCs Targeting Predictive Biomarkers

11 weeks پیش

—

Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Laura Alder, MD The recent approval of antibody drug conjugates (ADCs) has the potential to address unmet needs associated with second-line treatment options for non-small cell lung cancer, like limited benefits and substantial toxicity. But given the complex structure of ADCs, it’s important to identify biomarkers that can predict a patient’s response to therapy. That’s why the phase 1b TROPION-LUNG02 trial examined the effectiveness of Dato-DXd and HER3-DXd in the presence of predictive biomarkers. Joining Dr. Charles Turck to discuss the trial’s findings and implications is Dr. Laura Alder, Assistant Professor of Medicine at Duke University School of Medicine in Durham, North Carolina.…

Project Oncology®

1
Treating NSCLC with Durvalumab, Chemotherapy, and Novel Agents: Preliminary Results

12 weeks پیش

—

Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Thomas Egenod, MD In an effort to identify additional treatment options for resectable non-small cell lung cancer (NSCLC), the NeoCOAST-2 study is evaluating the efficacy and safety of combining durvalumab, chemotherapy, and novel agents in the neoadjuvant setting as well as combining durvalumab with novel agents in the adjuvant setting. Joining Dr. Charles Turck to share the preliminary results regarding the safety, pathological complete response, and major pathological response rates of these two approaches is study investigator Dr. Thomas Egenod, who presented the NeoCOAST-2 study at the 2024 World Conference on Lung Cancer.…

Project Oncology®

1
Evaluating Valemetostat and Dato-DXd for NSCLC: An Upcoming Trial

12 weeks پیش

—

Host: Jacob Sands, MD Guest: Alex Spira, MD, PhD, FACP Valemetostat is a novel therapy that’s demonstrated clinical efficacy and safety across multiple hematologic malignancies, but what role might it have in treating patients with advanced, unresectable, or metastatic non-squamous non-small cell lung cancer (NSCLC)? To find out, an upcoming trial is examining the efficacy and safety of combining valemetostat and datopotamab deruxtecan (Dato-DXd). Here with Dr. Jacob Sands to talk about the study’s design and next steps is Dr. Alex Spira, Director of the Thoracic and Phase I Program at Virginia Cancer Specialists Research Institute and a Clinical Assistant Professor at Johns Hopkins.…

Project Oncology®

1
Analyzing Dato-DXd for Non-Squamous NSCLC with Brain Metastases

12 weeks پیش

—

Host: Jacob Sands, MD Guest: Aaron Lisberg, MD Unfortunately, brain metastases are very common in patients with non-small cell lung cancer (NSCLC). That’s why the phase 3 TROPION-Lung01 trial examined the efficacy and safety of datopotamab deruxtecan (Dato-DXd) for advanced non-squamous NSCLC with brain metastases. Joining Dr. Jacob Sands to share the results presented at the 2024 ESMO Congress is thoracic medical oncologist Dr. Aaron Lisberg.…

Project Oncology®

1
Dato-DxD for NSCLC: A Review of Final Overall Survival Data from TROPION-Lung01

12 weeks پیش

—

Host: Jacob Sands, MD Guest: Aaron Lisberg, MD Docetaxel alone or in combination with ramucirumab is the current standard of care for the second-line treatment of non-small cell lung cancer (NSCLC), but there are several limitations of docetaxel-containing regimens. That’s why there’s interest in identifying new therapies like datopotamab deruxtecan (Dato-DXd), which was found to improve overall survival based on an interim analysis. But what are the latest findings? Here to share the final overall survival data on Dato-DXd from the TROPION-Lung01 trial are Drs. Jacob Sands and Aaron Lisberg, who worked together on this research that was presented at the 2024 World Conference on Lung Cancer.…

Project Oncology®

1
Understanding Heparin Resistance: Underlying Mechanisms and Alternative Treatment Options

13 weeks پیش

—

Guest: Cheryl Maier MD, PhD Heparin resistance occurs when patients don’t respond to anticoagulation as expected, even with what seems like the appropriate dose. Join Dr. Cheryl Maier, who spoke about this topic at the 2024 American Society of Hematology Annual Meeting, to learn more about testing methods, the role of antithrombin, and alternative treatments, like direct thrombin inhibitors. Dr. Maier is an Assistant Professor in the Department of Pathology and Laboratory Medicine at Emory University and the Medical Director of the Emory Special Coagulation Laboratory in Atlanta, Georgia.…

Project Oncology®

1
The Future of ITP Care: Exploring New Treatments

13 weeks پیش

—

Guest: Michele Lambert, MD, MSTR New treatments are on the horizon for patients with immune thrombocytopenia (ITP). Dr. Michele Lambert shares insights on how BTK inhibitors and immune-targeting drugs aim to address the root causes of ITP and offer more personalized care for patients. Dr. Lambert, the Medical Director of the Special Coagulation Laboratory and a physician in the Division of Hematology at Children’s Hospital of Philadelphia, presented on this topic at the 2024 American Society of Hematology Annual Meeting.…

Project Oncology®

1
Understanding iMCD Through RNA Sequencing

13 weeks پیش

—

Guest: Michael Gonzalez, PhD, MSc New research on the molecular mechanisms behind idiopathic multicentric Castleman disease (iMCD) through gene expression analysis of lymph node tissue has the potential to improve both diagnosis and treatment. Join Dr. Michael Gonzalez as he dives in on his recent findings, which he spoke about at the 2024 American Society of Hematology Annual Meeting. Dr. Gonzalez is the Associate Director of Basic and Translational Research at the University of Pennsylvania Center for Cytokine Storm Treatment and Laboratory and an Adjunct Professor at La Salle University.…

Project Oncology®

1
NSCLC Care: Predicting Response to Dato-DXd with a TROP2 Biomarker

13 weeks پیش

—

Host: Jacob Sands, MD Guest: Marina Garassino, MD Datopotamab deruxtecan (Dato-DXd) is a second-line antibody drug conjugate that could lead to improved progression-free survival in patients with advanced or metastatic non-small cell lung cancer. Given these potential benefits, it’s important to identify biomarkers that may predict a patient’s response to Dato-DXd, which was the focus of recent research presented at the 2024 World Conference on Lung Cancer. Here with Dr. Jacob Sands to discuss a new biomarker for TROP2 is Dr. Marina Garassino, Professor of Medicine and Director of the Thoracic Oncology Program at the University of Chicago.…

Project Oncology®

1
Diagnosing Castleman Disease: Key Considerations

14 weeks پیش

—

Guest: Mateo Bustamante Idiopathic multicentric Castleman disease (iMCD) is a rare, life-threatening condition. Early diagnosis through excisional biopsies is key for speeding up treatment and improve patient outcomes. Learn more with Mateo Bustamante, a Senior Clinical Data Analyst at the Center for Cytokine Storm Treatment and Laboratory at University of Pennsylvania’s Perelman School of Medicine.…

Project Oncology®

1
Improving Diagnosis of Castleman Disease: The Key Role of Stromal Cells

14 weeks پیش

—

Guest: Joshua Brandstadter, MD, PhD, MSc Castleman disease is difficult to diagnose and treat, with half of patients not responding to therapy. To address these challenges, Dr. Joshua Brandstadter discusses his research on how stromal cells play a role in the disease. Based at the University of Pennsylvania, Dr. Brandstadter is an Instructor of Medicine in the Division of Hematology and Oncology and the Director of Clinical Research for the Center of Cytokine Storm Treatment and Laboratory.…

به Player FM خوش آمدید!

Player FM در سراسر وب را برای یافتن پادکست های با کیفیت اسکن می کند تا همین الان لذت ببرید. این بهترین برنامه ی پادکست است که در اندروید، آیفون و وب کار می کند. ثبت نام کنید تا اشتراک های شما در بین دستگاه های مختلف همگام سازی شود.